Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction

Climacteric

Volumn 12, Issue 2, 2009, Pages 114-121

  Nijland, E A ^a   Nathorst Boos J ^b   Palacios, S ^c   Van De Weijer, P W ^d   Davis, S ^e   Stathopoulos, V M ^f   Birkhaeuser, M H ^g   Von Mauw, E ^h   Mulder, R J ^h   Weijmar Schultz, W C M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^d GELRE HOSPITALS   (Netherlands)

^e MONASH UNIVERSITY   (Australia)

^f Global Clinical Development   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

^h Clinical Development Department   (Netherlands)

Author keywords

Menopause; Tibolone; Tolerability; Transdermal estrogen progestogen therapy; Vaginal bleeding

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; PLACEBO; TIBOLONE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MASTALGIA; MORBIDITY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; TREATMENT DURATION; VAGINA BLEEDING;

ADMINISTRATION, CUTANEOUS; AGED; BREAST; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; PAIN; POSTMENOPAUSE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; UTERINE HEMORRHAGE;

EID: 61949385876     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802576666     Document Type: Article

References (26)

1. Nappi RE, Wawra K, Schmitt S. Hypoactive sexual desire disorder in postmenopausal women. Gynecol Endocrinol 2006;22:318-23
2. Kovalevsky G. Female sexual dysfunction and use of hormone therapy in postmenopausal women. Semin Reprod Med 2005;23:180-7
3. Nathorst-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 1997;26:15-20
4. Castelo-Branco C, Vicente J, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-8
5. Kloosterboer HJ. Tissue selectivity: the mechanism of action of tibolone. Maturitas 2004;48 (Suppl 1): S30-40
6. De Gooyer ME, Deckers GH, Schoonen WGEJ, Verheul HAM, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:21-30
7. Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554-9
8. Langer RD, Landgren BM, Rymer J, Helmond FA, for the OPAL Investigators. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006;195:1320-7
9. Huber J, Palacios S, Berglund L, et al. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886-93
10. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904-11
11. Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299-306
12. Gooyer de ME, Overklift Vaupel Kleyn GT, Smits KC, Ederveen AGH, Verheul HAM, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:55-62
13. Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas 2004;49:S5-15
14. Lundström E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
15. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;3:CD000402
16. Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf 1993;9:365-79
17. Roy S, Boostanfar R, Saadet P, Poysky J. Serum endocrine markers and psychosexual mood in postmenopausal women: the difference between transdermal and oral HRT. Climacteric 2002;5(Suppl 1): 198
18. Rogers RG, Simon JA, Ragavan VV. Combipatch® significantly improves Women's Sexual Quality of Life compared to Prempro™ in a randomized trial. Poster presented at the 10th World Congress on the Menopause. June 2002, Berlin, Germany.
19. Nijland EA, Weijmar Schultz WC, Nathorst-Böös J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized, active-controlled trial. J Sex Med 2008;5:646-56
20. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol- norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498-503
21. Samsioe G, Boschitsch E, Concin H, et al. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96weeks: a randomized openlabel study. Climacteric 2006;9:368-79
22. Hammar M, van de Weijer P, Franke H, Pornel B, von Mauw E, Nijland E. Tibolone and low dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. Br J Obstet Gynaecol 2007;114:1522-9
23. Archer DF, Navarro FJ, Leslie S, Mirkin S. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone and 17b-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells. Fertil Steril 2004;81:165-70
24. Genazzani AR, Schneider HP, Panay N, Nijland EA. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006;22:369-75
25. Harvey J, Scheurer C, Kawakami FT, Quebe-Fehling E, de Palacios PI, Ragavan VV. Hormone replacement therapy and breast density changes. Climacteric 2005;8:185-92
26. Hofling M, Carlström K, Svane G, Azavedo E, Kloosterboer H, Von Schoultz B. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels - an association with mammographic density. Gynecol Endocrinol 2005;20:110-15